Tokyo Tape
Sign in
← Oncolys BioPharma

Annual report

4588.TEDINET S100PNBN
Period2017-01-01 → 2017-12-31
Filed2022-11-17
StandardJapan GAAP
ConsolidatedNo
Data checks13 of 13 passed

Amends S100CP6F.

Key figures · 78
MetricValuePeriodScopeSource row
Revenue¥229m2017-01-01 → 2017-12-31StandaloneNet sales
Revenue¥178m2016-01-01 → 2016-12-31StandaloneNet sales
Revenue¥121m2015-01-01 → 2015-12-31dStandaloneNet sales (5-year summary)
Revenue¥29m2014-01-01 → 2014-12-31dStandaloneNet sales (5-year summary)
Revenue¥1m2013-01-01 → 2013-12-31dStandaloneNet sales (5-year summary)
Operating income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOperating income
Operating income−¥861m2016-01-01 → 2016-12-31StandaloneOperating income
Ordinary income−¥1.1bn2017-01-01 → 2017-12-31StandaloneOrdinary income
Ordinary income−¥864m2016-01-01 → 2016-12-31StandaloneOrdinary income
Ordinary income−¥855m2015-01-01 → 2015-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥726m2014-01-01 → 2014-12-31dStandaloneOrdinary income loss (5-year summary)
Ordinary income−¥625m2013-01-01 → 2013-12-31dStandaloneOrdinary income loss (5-year summary)
Profit before tax−¥1.1bn2017-01-01 → 2017-12-31StandaloneIncome before income taxes
Profit before tax−¥928m2016-01-01 → 2016-12-31StandaloneIncome before income taxes
Net income−¥1.1bn2017-01-01 → 2017-12-31StandaloneProfit loss
Net income−¥931m2016-01-01 → 2016-12-31StandaloneProfit loss
Net income−¥857m2015-01-01 → 2015-12-31dStandaloneNet income loss (5-year summary)
Net income−¥739m2014-01-01 → 2014-12-31dStandaloneNet income loss (5-year summary)
Net income−¥636m2013-01-01 → 2013-12-31dStandaloneNet income loss (5-year summary)
Total assets¥3.5bnat 2017-12-31StandaloneAssets
Total assets¥3.1bnat 2016-12-31StandaloneAssets
Total assets¥4.0bnat 2015-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.0bnat 2014-12-31dStandaloneTotal assets (5-year summary)
Total assets¥5.7bnat 2013-12-31dStandaloneTotal assets (5-year summary)
Total liabilities¥594mat 2017-12-31StandaloneLiabilities
Total liabilities¥523mat 2016-12-31StandaloneLiabilities
Net assets / equity¥2.9bnat 2017-12-31StandaloneNet assets
Net assets / equity¥2.6bnat 2016-12-31StandaloneNet assets
Net assets / equity¥3.5bnat 2015-12-31dStandaloneNet assets
Net assets / equity¥4.4bnat 2014-12-31dStandaloneNet assets (5-year summary)
Net assets / equity¥5.1bnat 2013-12-31dStandaloneNet assets (5-year summary)
Cash and deposits¥2.9bnat 2017-12-31StandaloneCash and deposits
Cash and deposits¥2.6bnat 2016-12-31StandaloneCash and deposits
Cash & equivalents¥1.9bnat 2017-12-31StandaloneCash and cash equivalents
Cash & equivalents¥1.4bnat 2016-12-31StandaloneCash and cash equivalents
Cash & equivalents¥2.1bnat 2015-12-31dStandaloneCash and cash equivalents
Cash & equivalents¥1.2bnat 2014-12-31dStandaloneCash and cash equivalents (5-year summary)
Cash & equivalents¥5.4bnat 2013-12-31dStandaloneCash and cash equivalents (5-year summary)
Operating cash flow−¥1.1bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥903m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in operating activities
Operating cash flow−¥756m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥814m2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Operating cash flow−¥599m2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in operating activities (5-year summary)
Investing cash flow¥132m2017-01-01 → 2017-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥257m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in investment activities
Investing cash flow¥1.8bn2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow−¥3.4bn2014-01-01 → 2014-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Investing cash flow¥110m2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in investing activities (5-year summary)
Financing cash flow¥1.5bn2017-01-01 → 2017-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow¥6m2016-01-01 → 2016-12-31StandaloneNet cash provided by used in financing activities
Financing cash flow−¥120m2015-01-01 → 2015-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow−¥233,0002014-01-01 → 2014-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
Financing cash flow¥5.4bn2013-01-01 → 2013-12-31dStandaloneNet cash provided by used in financing activities (5-year summary)
EPS (basic)¥-106.232017-01-01 → 2017-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-101.182016-01-01 → 2016-12-31StandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-93.352015-01-01 → 2015-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-80.552014-01-01 → 2014-12-31dStandaloneBasic earnings loss per share (5-year summary)
EPS (basic)¥-94.332013-01-01 → 2013-12-31dStandaloneBasic earnings loss per share (5-year summary)
Net assets per share¥263.54at 2017-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥283.43at 2016-12-31StandaloneNet assets per share (5-year summary)
Net assets per share¥381.27at 2015-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥476.03at 2014-12-31dStandaloneNet assets per share (5-year summary)
Net assets per share¥561.17at 2013-12-31dStandaloneNet assets per share (5-year summary)
Equity ratio82.9%at 2017-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio82.7%at 2016-12-31StandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2015-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio87.2%at 2014-12-31dStandaloneEquity to asset ratio (5-year summary)
Equity ratio89.3%at 2013-12-31dStandaloneEquity to asset ratio (5-year summary)
Shares issued11,086,000at 2017-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,234,600at 2016-12-31StandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,800at 2015-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,183,200at 2014-12-31dStandaloneTotal number of issued shares (5-year summary)
Shares issued9,076,900at 2013-12-31dStandaloneTotal number of issued shares (5-year summary)
Employees29at 2017-12-31StandaloneNumber of employees
Employees30at 2016-12-31StandaloneNumber of employees
Employees29at 2015-12-31dStandaloneNumber of employees
Employees28at 2014-12-31dStandaloneNumber of employees
Employees22at 2013-12-31dStandaloneNumber of employees

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 24
SegmentItemPeriodValue
Reconciling Itemsreconcilingdepreciation2017-01-01 → 2017-12-31¥1m
Reconciling Itemsreconcilingsegment profit2017-01-01 → 2017-12-31−¥537m
Diagnostic Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥33m
Diagnostic Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥104m
Pharmaceutical Divisionreportable segmentrevenue2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentrevenue external2017-01-01 → 2017-12-31¥197m
Pharmaceutical Divisionreportable segmentsegment profit2017-01-01 → 2017-12-31−¥438m
Total Of Reportable Segments And Otherssegment totalrevenue2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalrevenue external2017-01-01 → 2017-12-31¥229m
Total Of Reportable Segments And Otherssegment totalsegment profit2017-01-01 → 2017-12-31−¥542m
Reconciling Itemsreconcilingdepreciation2016-01-01 → 2016-12-31¥4m
Reconciling Itemsreconcilingsegment profit2016-01-01 → 2016-12-31−¥438m
Diagnostic Divisionreportable segmentdepreciation2016-01-01 → 2016-12-31¥11m
Diagnostic Divisionreportable segmentrevenue2016-01-01 → 2016-12-31¥60m
Diagnostic Divisionreportable segmentrevenue external2016-01-01 → 2016-12-31¥60m
Diagnostic Divisionreportable segmentsegment profit2016-01-01 → 2016-12-31−¥105m
Pharmaceutical Divisionreportable segmentrevenue2016-01-01 → 2016-12-31¥119m
Pharmaceutical Divisionreportable segmentrevenue external2016-01-01 → 2016-12-31¥119m
Pharmaceutical Divisionreportable segmentsegment profit2016-01-01 → 2016-12-31−¥318m
Total Of Reportable Segments And Otherssegment totaldepreciation2016-01-01 → 2016-12-31¥11m
Total Of Reportable Segments And Otherssegment totalrevenue2016-01-01 → 2016-12-31¥178m
Total Of Reportable Segments And Otherssegment totalrevenue external2016-01-01 → 2016-12-31¥178m
Total Of Reportable Segments And Otherssegment totalsegment profit2016-01-01 → 2016-12-31−¥423m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 712
ItemContextValueUnit
Telephone number address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person address of registered headquarter cover pageFilingDateInstant
Original text (Japanese)取締役財務担当　　小林　直樹
Nearest place of contact cover pageFilingDateInstant
Original text (Japanese)東京都港区虎ノ門四丁目１番28号
Telephone number nearest place of contact cover pageFilingDateInstant
Original text (Japanese)03－5472－1578(代表)
Name of contact person nearest place of contact cover pageFilingDateInstant
Original text (Japanese)取締役財務担当　　小林　直樹
Place for public inspection cover page (text)FilingDateInstantText · Plus
Edinet codeFilingDateInstantE30058
Fund codeFilingDateInstant－
Security codeFilingDateInstant45880
Filer name in japaneseFilingDateInstant
Original text (Japanese)オンコリスバイオファーマ株式会社
Filer name in englishFilingDateInstantOncolys BioPharma Inc.
Fund name in japaneseFilingDateInstant－
Fund name in englishFilingDateInstant－
Cabinet office ordinanceFilingDateInstant
Original text (Japanese)企業内容等の開示に関する内閣府令
Document typeFilingDateInstant
Original text (Japanese)第三号様式
Accounting standardsFilingDateInstantJapan GAAP
Whether consolidated financial statements are preparedFilingDateInstantfalse
Industry code when consolidated financial statements are prepared in accordance with industry specific regulationsFilingDateInstant－
Industry code when financial statements are prepared in accordance with industry specific regulationsFilingDateInstantcte
Current fiscal year start dateFilingDateInstant2017-01-01
Current period end dateFilingDateInstant2017-12-31
Type of current periodFilingDateInstantFY
Current fiscal year end dateFilingDateInstant2017-12-31
Previous fiscal year start dateFilingDateInstant2016-01-01
Comparative period end dateFilingDateInstant2016-12-31
Previous fiscal year end dateFilingDateInstant2016-12-31
Next fiscal year start dateFilingDateInstant－
End date of quarterly or semi annual period of next fiscal yearFilingDateInstant－
Amendment flagFilingDateInstanttrue
Identification of document subject to amendmentFilingDateInstantS100CP6F
Report amendment flagFilingDateInstanttrue
Xbrl amendment flagFilingDateInstantfalse
Business results of reporting company (text)FilingDateInstantText · Plus
Company history (text)FilingDateInstantText · Plus
Description of business (text)FilingDateInstantText · Plus
Overview of affiliated entities na (text)FilingDateInstantText · Plus
Information about employees (text)FilingDateInstantText · Plus
Overview of business results (text)FilingDateInstantText · Plus
Overview of production orders received and sales (text)FilingDateInstantText · Plus
Business policy business environment issues to address etc (text)FilingDateInstantText · Plus
Business risks (text)FilingDateInstantText · Plus
Critical contracts for operation (text)FilingDateInstantText · Plus
Research and development activities (text)FilingDateInstantText · Plus
Analysis of financial position operating results and cash flows (text)FilingDateInstantText · Plus
Overview of capital expenditures etc (text)FilingDateInstantText · Plus
Major facilities (text)FilingDateInstantText · Plus
Planned additions retirements etc of facilities (text)FilingDateInstantText · Plus
Total number of shares (text)FilingDateInstantText · Plus
Issued shares total number of shares etc (text)FilingDateInstantText · Plus
Subscription rights to shares etc (text)FilingDateInstantText · Plus

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 13 of 13 passed
balance sheet identitynon_consolidated 2016-12-31pass rounding
balance sheet identitynon_consolidated 2017-12-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsnon_consolidated 2015-12-31pass
statement vs summary · net assetsnon_consolidated 2016-12-31pass
statement vs summary · net assetsnon_consolidated 2017-12-31pass
statement vs summary · operating cash flownon_consolidated 2016-01-01/2016-12-31pass
statement vs summary · operating cash flownon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · revenuenon_consolidated 2016-01-01/2016-12-31pass
statement vs summary · revenuenon_consolidated 2017-01-01/2017-12-31pass
statement vs summary · total assetsnon_consolidated 2016-12-31pass
statement vs summary · total assetsnon_consolidated 2017-12-31pass